Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer

Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by... Purpose Thyroglobulin (Tg) may be released from damaged residual thyroid tissues after radioactive iodine (RAI) therapy in patients with differentiated thyroid carcinoma (DTC). We investigated whether altered levels of serum Tg after recombinant human thyrotropin (rhTSH)-aided RAI therapy could be a prognostic marker in patients with DTC. Methods We evaluated 68 patients who underwent RAI therapy after total thyroidectomy. Serum Tg levels were measured just before RAI administration (D0Tg) and 7 days after RAI therapy (D7Tg). Patients with a D0Tg level greater than 2.0 ng/mL were excluded to more precisely evaluate the injury effect of RAI in small remnant tissues. The ratioTg was defined as the D7Tg level divided by that on D0Tg. The therapeutic responses were classified as acceptable or non-acceptable. Finally, we investigated which clinicopathologic parameters were associated with therapeutic response. Results At the follow-up examination, an acceptable response was observed in 50 patients (73.5%). Univariate analysis revealed significant differences in N stage (P = 0.003) and ratioTg (acceptable vs. non-acceptable responses, 21.9 ± 33.6 vs. 3.8 ± 6.5; P = 0.006). In multivariate analysis, only ratioTg significantly predicted an acceptable response (odds ratio 1.104; 95% confidence interval 1.005–1.213; P = 0.040). A ratioTg above 3.5 predicted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/response-prediction-of-altered-thyroglobulin-levels-after-radioactive-K07P0IBEb6
Publisher
Springer Journals
Copyright
Copyright © 2018 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-018-0528-7
Publisher site
See Article on Publisher Site

Abstract

Purpose Thyroglobulin (Tg) may be released from damaged residual thyroid tissues after radioactive iodine (RAI) therapy in patients with differentiated thyroid carcinoma (DTC). We investigated whether altered levels of serum Tg after recombinant human thyrotropin (rhTSH)-aided RAI therapy could be a prognostic marker in patients with DTC. Methods We evaluated 68 patients who underwent RAI therapy after total thyroidectomy. Serum Tg levels were measured just before RAI administration (D0Tg) and 7 days after RAI therapy (D7Tg). Patients with a D0Tg level greater than 2.0 ng/mL were excluded to more precisely evaluate the injury effect of RAI in small remnant tissues. The ratioTg was defined as the D7Tg level divided by that on D0Tg. The therapeutic responses were classified as acceptable or non-acceptable. Finally, we investigated which clinicopathologic parameters were associated with therapeutic response. Results At the follow-up examination, an acceptable response was observed in 50 patients (73.5%). Univariate analysis revealed significant differences in N stage (P = 0.003) and ratioTg (acceptable vs. non-acceptable responses, 21.9 ± 33.6 vs. 3.8 ± 6.5; P = 0.006). In multivariate analysis, only ratioTg significantly predicted an acceptable response (odds ratio 1.104; 95% confidence interval 1.005–1.213; P = 0.040). A ratioTg above 3.5 predicted

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Jun 4, 2018

References

  • Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma
    Muratet, JP; Giraud, P; Daver, A; Minier, JF; Gamelin, E; Larra, F
  • Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma
    Kim, TY; Kim, WB; Kim, ES; Ryu, JS; Yeo, JS; Kim, SC
  • Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer
    Bernier, MO; Morel, O; Rodien, P; Muratet, JP; Giraud, P; Rohmer, V
  • Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma
    Park, HJ; Jeong, GC; Kwon, SY; Min, JJ; Bom, HS; Park, KS
  • Serum thyroglobulin level after radioiodine therapy (day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer
    Kim, YI; Im, HJ; Paeng, JC; Cheon, GJ; Kang, KW; Lee, DS
  • Iodine uptake patterns on post-ablation whole body scans are related to elevated serum thyroglobulin levels after radioactive iodine therapy in patients with papillary thyroid carcinoma
    Jeong, GC; Song, M; Park, HJ; Min, JJ; Bom, HS; Cho, SG
  • Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later
    Melo, M; Costa, G; Ribeiro, C; Carrilho, F; Martins, MJ; Rocha, AG
  • Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy
    Park, HJ; Min, JJ; Bom, HS; Kim, J; Song, HC; Kwon, SY
  • Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth
    Rosario, PW; Salles, DS; Purisch, S
  • Acute radiation thyroiditis
    Nishiyama, K; Kozuka, T; Higashihara, T; Miyauchi, K; Okagawa, K
  • Recent developments in the radiobiology of cellular membranes
    Cramp, WA; Yatvin, MB; Harms-Ringdahl, M
  • Membranes as sensitive targets in thymocyte apoptosis
    Ramakrishnan, N; McClain, DE; Catravas, GN
  • Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma
    Bachelot, A; Cailleux, AF; Klain, M; Baudin, E; Ricard, M; Bellon, N
  • The cut-off level of recombinant human TSH-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer
    Kowalska, A; Pałyga, I; Gąsior-Perczak, D; Walczyk, A; Trybek, T; Słuszniak, A
  • Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system
    Tuttle, RM; Tala, H; Shah, J; Leboeuf, R; Ghossein, R; Gonen, M
  • American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
    Haugen, BR; Alexander, EK; Bible, KC; Doherty, GM; Mandel, SJ; Nikiforov, YE
  • Molecular advances in thyroglobulin disorders
    Rivolta, CM; Targovnik, HM
  • Strategies of radioiodine ablation in patients with low-risk thyroid cancer
    Schlumberger, M; Catargi, B; Borget, I; Deandreis, D; Zerdoud, S; Bridji, B
  • Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer
    Mallick, U; Harmer, C; Yap, B; Wadsley, J; Clarke, S; Moss, L